WuXi XDC Wins GMP Release for First Overseas Site in Singapore
Singapore – September 21, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has secured GMP release for its Singapore manufacturing site at Tuas Biomedical Park, marking the bioconjugate CRDMO's first overseas facility just two and a half years after the site was announced in March 2024.
BCM3 dual-function line and DP4 drug product facility clear GMP release
The 25,000-square-meter site achieved GMP release for both its BCM3 antibody intermediate and conjugated drug substance production line and its DP4 drug product facility in August 2026. BCM3 supports batch sizes from 200 L to 2,000 L for antibody intermediates and up to 2,000 L for conjugated drug substances, operating under FDA, EMA and NMPA standards. A second line, BCM4, is slated for GMP release by the end of 2026 with a maximum single-batch capacity of 500 L for conjugated drug substance.
